SMIMIF115U Market Access for Pharmaceutical Products – trends and challenges
Master's Programme in Industrial Drug Development - elective
The course is preapproved as an elective in the Master of
Industrial Drug Development (MIND) programme, the Master of
Pharmaceutical Regulatory Affairs (MPRA) programme and Master of
Drug Management (MDM) programme and open for freelance students who
meet the admission criteria.
In the competitive world of pharmaceutical sales, developing a
market access strategy and communicating the value of the brands to
the ‘payers’ is at the top of the agenda. In recent years, the
field of pricing and reimbursement of pharmaceuticals has become
more complex and challenging.
The economic crisis, austerity measures and general demographic
changes (aging population) coupled with newer and more expensive
drugs has contributed to bigger hurdles in securing market access.
Decisions are now increasingly made on cost-effectiveness and
cost-containment rationales, whereas only safety and efficacy
guided the decision to a greater degree years ago.
Although everyone seems to be talking about market access, very few
are able to define it. Who are the new key stakeholders, exactly?
Is it no longer the prescribers that decide which drug a patient
should use? Is market access only about containing costs for the
public budgets or are the benefits for patients and society as
well?
This course will provide insight into the key principles and a practical understanding of ‘market access’ as it relates to the pharmaceutical industry. The course starts with an overview of the key stakeholders and current trends in the global market access of pharmaceuticals followed by a review of the hot topics, challenges and relevant issues through a combination of lectures, discussions, group work, and case studies.
The topics include:
- Introduction to market access - Marketing trends, defining global market access for the 21st century, its importance for optimizing product launches & its implications for the entire organization
- Core concepts of market access – defining the concepts, theories and methods relevant for the pharmaceutical industry
- Value generation – the role of clinical trials, real-world evidence, life-cycle management, health economics
- Stakeholders – who they are, what are their perspectives, how and when to engage with “payers”
- Health economic aspects of marketing – economic and financial considerations, core concepts and vocabulary
- Pricing and reimbursement – global vs. local optimization, reference pricing systems in various markets.
- Competencies – which skills and training are necessary to develop effective personnel; cross-functional teams
- Patient centricity – the importance of understanding that the end-user must be the focal point during the entire process
On completion of the course participants should be able to:
Knowledge
- Explain how health policy affects and creates a framework for market access and the use of pharmaceuticals
- Identify and describe the key challenges of obtaining market access
- Identify major stakeholders & their influence on the drug reimbursement and prescription process.
- Explain, reflect upon, and discuss the importance of market access and its relation to the entire pharmaceutical organization
Skill
- Evaluate the relationship and dynamics of regulatory policies, and their implications for reimbursement of new pharmaceutical products
- Describe, assess and discuss the various perspectives and potential conflicts of major actors associated with pharmaceutical market access
Competence
- Participate in professional multi-disciplinary groups and be able to contribute with a market access perspective on pharmaceuticals
The compulsory syllabus comprises a collection of review papers, textbook chapters and case studies corresponding to approximately 500 pages (extra 200 pages self-selected literature for the optional term paper).
• A relevant bachelor degree or equivalent
• A minimum of 2 years of relevant job experience
• Proficiency in English
- Category
- Hours
- Class Instruction
- 40
- Exam
- 20
- Preparation
- 22,5
- Total
- 82,5
Application deadline 28 May 2015
Apply here
- Credit
- 3 ECTS
- Type of assessment
- Written assignmentAn essay (case study) based on an extended literature list. The essay must be 8-15 pages.
- Exam registration requirements
Active participation in the course is a prerequisite for assessment.
- Marking scale
- passed/not passed
- Censorship form
- No external censorship
- Exam period
Deadline for submission of case study: 1 October 2015 at 4 pm.
- Re-exam
1 November 2015.
Criteria for exam assesment
To pass the exam, the participant must have:
- Written a comprehensive and structured report on a selected case in their own words based on relevant literature.
- Demonstrated an ability to find, understand and report relevant literature for the selected case.
- Demonstrated knowledge of the principles and terms used in the field of market access for pharmaceutical products.
- Demonstrated an understanding of the central concepts and disciplines relevant for the selected case.
Course information
- Language
- English
- Course code
- SMIMIF115U
- Credit
- 3 ECTS
- Level
- Part Time Master
- Duration
- 10-14 August 2015
- Placement
- Summer
- Schedule
- 5 days, 9:00 – 17:00
- Course capacity
- 25 participants
- Continuing and further education
- Price
EUR 2,600 DKK 19,000. Fee includes teaching, course materials, and all meals during course and examination. Participants already enrolled in a Master's programme at the Faculty of Health and Medical Sciences, University of Copenhagen will get a 15% discount on the course fee. (EUR 2,200/DKK 16,000).
- Study board
- Study Board for Part-time Master’s Programmes of Pharmaceutical Sciences
Contracting department
- Department of Pharmacy
Course responsibles
- Janine Marie Traulsen
(janine.traulsen@sund.ku.dk)
Marlene Gyldmark, Head of Modelling, Outcomes Research, Statistics and Epidemiology, F. Hoffmann-La Roche AG
Lecturers
Torsten E. Christensen, Director, Market Access – Value
Communication Novo Nordisk A/S
Jørgen Clausen, Chief Economist, The Danish Association of the
Pharmaceutical Industry
Ulla Kirkegaard Madsen, Pharmacist, Executive Secretariat,
Pharmacies and Reimbursement Division, Danish Health and Medicines
Authority
Finn Børlum Kristensen, Secretariat Director, EUnetHTA Secretariat
Signe Høngaard Thybo, Healthcare Partnering Manager, Roche a/s
Denmark
Elvira Mueller, Vice President Market Access and Health Economics,
LA-SER Group, Germany
Additional speakers may be included.